France's Sanofi-Aventis to Produce H5N1 Vaccine
Posted on: Friday, 11 November 2005, 09:00 CST
France's Sanofi-Aventis to produce H5N1 vaccine
PARIS, Nov. 10 (Xinhua) -- French Sanofi-Aventis pharmaceutical group announced Thursday that it has signed a deal with French Health Ministry to produce prototype vaccine for humans to treat H5N1 virus.
A spokesman for the company said Sanofi-Aventis would supply before the end of the year 1.4 million doses of "pre-pandemic" or "prototype" vaccine to treat the strain of bird flu known as H5N1 and that it would supply "up to 28 million vaccination doses if a pandemic was declared, once the virus that caused the pandemic was identified."
The strain of bird flu known as H5N1 which has killed more than 60 people in Asia and the spread of H5N1 in birds has now reached to Europe and the Gulf.
Source: Xinhua News Agency - CEIS
Related Articles
- Baxter Announces Safety and Immunogenicity Results From Phase I/II Clinical Trial of Cell-Based Candidate H5N1 Pandemic Vaccine
- Sanofi-Aventis and UCB Sign a Co-Promotion Agreement for Xyzal(R) in the United States
- Baxter Initiates Clinical Study With Cell-Based Candidate H5N1 Pandemic Vaccine
- Sanofi-Aventis Announces Update to Ketek(R) (Telithromycin) U.S. Prescribing Information
- Adjuvanted Formulation of Sanofi Pasteur H5N1 Pandemic Influenza Vaccine Candidate Demonstrates Significant Immune Response
- Agreement Between Sanofi-Aventis and Roche to Produce Shikimic Acid
- Sanofi-Aventis and Regeneron Pharmaceuticals Expand Their VEGF Trap Oncology Collaboration to Japan
- Pfizer and Sanofi-Aventis Statement on Status of Exubera
- Pfizer and the Sanofi-Aventis Group Seek Approval to Market Exubera(R) in the United States
- Sanofi-Aventis Receives FDA Approval for New ELOXATIN(TM) Formulation
 |
 |
User Comments (0)
RSS Feeds